Byline: Evan Pondel Staff Writer THOUSAND OAKS - Amgen Inc. bought two of Roche's drugs for $137.5 million, the company said Wednesday, carving out a substantial foothold in Europe for the biotechnology giant. The deal parallels Immunex Corp.'s agreement last week ...

THOUSAND OAKS, Calif. -- Amgen Inc. (NASDAQ:AMGN), the world's largest biotechnology company, today announced the appointment of Jim Daly to the new position of senior vice president, North America Commercial Operations. Daly, formerly vice president and general ...

Amgen's Fourth Quarter 2006 Adjusted Earnings Per Share (EPS) Increased 20 Percent to $0.90; Full Year 2006 Adjusted EPS Increased 22 Percent to $3.90Fourth Quarter 2006 GAAP EPS Increased 8 Percent to $0.71 and Full Year 2006 GAAP EPS Decreased 15 Percent to $2.48...

Business Editors & Health/Medical Writers HUNTSVILLE, Ala.--(BW HealthWire)--June 12, 2001 Shearwater shearwater, common name for members of the family Procellariidae, gull-like sea birds related to the petrel and the albatross and including the fulma...

New Data on Targeted and Supportive Care Cancer Therapies Underscores Amgen's Commitment to Patients THOUSAND OAKS, Calif. -- Amgen (NASDAQ:AMGN), today announced several presentations of interest featuring its portfolio of supportive care, and therapeutic age...

BARCELONA, Spain -- Amgen (NASDAQ:AMGN) today announced results from an integrated analysis showing primary prophylactic use of Neulasta([R]) (pegfilgrastim), a granulocyte colony stimulating factor (G-CSF), with unique neutrophil-mediated clearance, decreased f...

Business Editors THOUSAND OAKS, Calif. and HOUSTON--(BUSINESS WIRE)--March 14, 2002 Amgen (Nasdaq:AMGN), the world's largest biotechnology company, has signed a multi-year agreement with US Oncology, Inc., (Nasdaq:USON), the nation's largest health-care network ded...

MIAMI BEACH, Fla. -- Study Evaluates 928 Breast Cancer Patients Receiving Neulasta(R) In The First and Subsequent Cycles of Moderately Myelosuppressive myelosuppressive /my·elo·sup·pres·sive/ (-su-pres´iv) 1. causing bone marrow suppression. 2. an agent tha...

Prostate Cancer Non-Hodgkin's Lymphoma Parkinson's Disease ...

According to the Centers for Disease Control and Prevention (CDC), kidney disease is the ninth leading cause of death in the United States (U.S.). Approximately 19 million adults in the U.S. have chronic kidney disease (CKD) and millions more are at risk of developing...

IN THIS ARTICLE, you'll learn about eight more new drugs marketed in the first half of 2002. (For details on other new drugs first marketed in that period, see "New Drugs2003, Part I" in the February issue of Nursing2003.) Among the most significant are: ...

DRUG NEWS ...

ORLANDO, Fla. -- Amgen Inc., (NASDAQ:AMGN) the world's largest biotechnology company, today announced that an initial report from a study of 701 older cancer patients with solid tumors demonstrates Neulasta(R) (pegfilgrastim) administered beginning in the first cycle ...

AHEAD OF FORECASTS, Amgen has received its third US drug approval in six months by gaining the nod from the Food & Drug Administration (FDA) for Neulasta (pegfilgrastim), a longer-acting version of its $1.3 billion immunity-boosting drug Neupogen (filgrastim)...

HORSHAM, Pa. -- Neose Technologies, Inc. (Nasdaq GM:NTEC) today announced that a GlycoPEG-GCSF Phase I clinical abstract submitted by the Company's collaborative partner, BioGeneriX AG, has been accepted for a poster presentation at the IXth World Conference on Clinic...